JTT-861
/ Japan Tobacco
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
October 16, 2025
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial primary completion date: Feb 2027 ➔ Aug 2026
Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
April 25, 2025
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial completion date: Sep 2025 ➔ Feb 2027 | Trial primary completion date: Sep 2025 ➔ Feb 2027
Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
September 20, 2024
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects with Heart Failure with Reduced Ejection Fraction
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial primary completion date: Jun 2025 ➔ Sep 2025
Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
May 03, 2024
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial completion date: Jun 2025 ➔ Sep 2025 | Initiation date: Aug 2023 ➔ Dec 2023
Trial completion date • Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure
January 01, 2024
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc.
Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
November 15, 2023
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Phase classification: P2a ➔ P2
Phase classification • Cardiovascular • Congestive Heart Failure • Heart Failure
August 30, 2023
POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
(clinicaltrials.gov)
- P2a | N=300 | Recruiting | Sponsor: Akros Pharma Inc.
New P2a trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 7
Of
7
Go to page
1